Ticker	Volume	Price	Price Delta
DJIA	15,296.50	+2.00	0.01%
S&P 500	1,647.07	-3.44	-0.21%
Nasdaq	3,455.99	-3.42	-0.10%

Ticker

Volume

Price

Price Delta

DJIA

15,296.50

+2.00

0.01%

S&P 500

1,647.07

-3.44

-0.21%

Nasdaq

3,455.99

-3.42

-0.10%

Ticker	Volume	Price	Price Delta
STOXX 50	2,764.29	-12.49	-0.45%
FTSE 100	6,654.34	-42.45	-0.63%
DAX	8,305.32	-46.66	-0.56%

Ticker

Volume

Price

Price Delta

STOXX 50

2,764.29

-12.49

-0.45%

FTSE 100

6,654.34

-42.45

-0.63%

DAX

8,305.32

-46.66

-0.56%

Ticker	Volume	Price	Price Delta
Nikkei	14,612.50	+128.47	0.89%
Hang Seng	22,618.70	-51.01	-0.23%
S&P/ASX 200	4,983.50	-78.95	-1.56%

Ticker

Volume

Price

Price Delta

Nikkei

14,612.50

+128.47

0.89%

Hang Seng

22,618.70

-51.01

-0.23%

S&P/ASX 200

4,983.50

-78.95

-1.56%

AstraZeneca May Advance at Least 8 Drugs to Final Tests by 2015

By Andrea Gerlin - 2012-07-12T15:54:22Z

AstraZeneca Plc (AZN) aims to advance at least eight medicines into late-stage tests within three years, one of its top research and development executives said today.

“We’ve set our R&D organization a goal of delivering eight to 11 Phase 3 projects,” Menelas N. Pangalos, executive vice president of the company’s Innovative Medicine Research Units, told reporters at a briefing in London.

“That’s more than we’ve ever done and that’s going to make us more competitive in terms of our peer group,” Pangalos said.

The company also made two announcements on early-stage research today. AstraZeneca bought a portfolio of potential nervous-system disorder treatments from Link Medicine Corp., and said it will participate in an alliance of four academic laboratories studying a risk factor for Alzheimer’s disease.

London-based AstraZeneca is the U.K.’s second-biggest drugmaker.

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.